Vireo Growth (VREOF) EBITDA Margin (2020 - 2026)
Vireo Growth (VREOF) posted EBITDA Margin of 8.47% for Q1 2026, up 588.13% sequentially from 1.74% in Q4 2025, and up 31.0% YoY from 6.47% in Q1 2025.
Vireo Growth (VREOF) EBITDA Margin (2020 - 2026) Analysis & Trends
Vireo Growth has reported EBITDA Margin for 7 years, with the latest figure at 8.47% in Q1 2026.
- Quarterly EBITDA Margin rose 31.0% year-over-year to 8.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.71% (down 912.0% YoY) and the FY2025 annual result came in at 0.39%, down 1404.0% from the prior year.
- EBITDA Margin improved to 8.47% in Q1 2026 per VREOF's latest filing, from 1.74% in the prior quarter.
- Over five years, EBITDA Margin peaked at 23.8% in Q3 2023 and troughed at 49.62% in Q1 2022.
- A 5-year average of 3.75% and a median of 1.93% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin surged 6416 bps in 2022, then plunged 2728 bps in 2025.
- Over 5 years, EBITDA Margin stood at 3.69% in 2022, then surged by 504 bps to 22.26% in 2023, then slumped by 115 bps to 3.36% in 2024, then soared by 48 bps to 1.74% in 2025, then jumped by 588 bps to 8.47% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 8.47%, 1.74%, and 0.88% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Vireo Growth | 492.35 Mn | 350.05 Mn | 95.30 Mn | -2.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.47% |
| Dec 31, 2025 | -1.74% |
| Sep 30, 2025 | 0.88% |
| Jun 30, 2025 | -4.20% |
| Mar 31, 2025 | 8.16% |
| Dec 31, 2024 | -3.36% |
| Sep 30, 2024 | 15.30% |
| Jun 30, 2024 | 23.08% |
| Mar 31, 2024 | 19.76% |
| Dec 31, 2023 | 22.26% |
| Sep 30, 2023 | 23.80% |
| Jun 30, 2023 | -5.16% |
| Mar 31, 2023 | 1.93% |
| Dec 31, 2022 | 3.69% |
| Sep 30, 2022 | -1.00% |
| Jun 30, 2022 | 1.46% |
| Mar 31, 2022 | -49.62% |
| Dec 31, 2021 | -60.47% |
| Sep 30, 2021 | -30.90% |
| Jun 30, 2021 | -22.82% |